A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Leflunomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 23 Dec 2016 Planned number of patients changed from 42 to 39.
- 04 Nov 2015 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2017 as reported by ClinicalTrials.gov record.
- 04 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.